Kamalika Mazumder
Research Subjects
Kamalika Mazumder has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Poulomi Biswas
Eminent College of Pharmaceutical Technology, Kolkata, India
3 shared publications - Kaushik Biswas
Eminent College of Pharmaceutical Technology, Kolkata, India
2 shared publications - Pankaj Paul
Eminent College of Pharmaceutical Technology, Kolkata, India
2 shared publications - Priyanka Chakraborty
BCDA College of Pharmacy & Technology, Hridaypur, 78/1, Jessore Road, Hridaypur, Kolkata, 700127, India
2 shared publications - Sandip Dolui
Eminent College of Pharmaceutical Technology, Moshpukr, Barbaria, Paschim Khilkapur, Barasat, Jagannathpur, West Bengal 700126, India, India
2 shared publications - Sangita Palai
Department of Pharmacognosy, Eminent College of Pharmaceutical Technology
2 shared publications
Latest Publications
- 5 July 2026
- Published by Taylor & Francis in Future Microbiology
- Vol. 21 (9) , 1-19
Mechanistic insights into the inhibition of biofilm formation and antibacterial action of endophytic Streptomyces strain KJ7TB2 isolated from the Indian Sundarbans Mangrove estuary
To explore the mechanism involved in the inhibition of biofilm formation and antibacterial action of endophytic Streptomyces sp. isolated from the Indian Sundarbans Mangrove Forest. In this study, Streptomyces sp. KJ7TB2 was isolated from the Indian Sundarbans. An ethyl acetate extract was subjected for GC-MS profiling. The mechanisms of antibacterial and antibiofilm action were also explored. In-silico molecular docking and dynamics simulation analyses were performed. The GC-MS analysis of the extract revealed 14 distinct bioactive secondary metabolites. The extract exhibited potent MIC values of 250 μg/mL and 125 μg/mL against Escherichia coli MTCC 1195 and Pseudomonas aeruginosa ATCC 27853. Antibiofilm investigation further revealed inhibition of biofilm formation in both pathogens especially in E. coli MTCC 1195, likely by disrupting initial surface adhesion and exopolysaccharide synthesis. Also, the extract inhibited swarming motility, suggesting interference with flagella-driven motility and quorum sensing. The brine shrimp lethality assay confirmed a favorable safety profile, recording limited mortality (36.84% at 2×MIC over 24 h). In-silico molecular docking and dynamics simulation analyses exhibited robust affinity for two key biofilm-associated proteins, exhibiting significant binding energy (ΔG). The study highlights Streptomyces sp. KJ7TB2 as a potential source for the discovery of safe, potent therapeutics.
- 5 July 2026
- Published by Taylor & Francis in Future Microbiology
- Vol. 21 (9) , 1-19
Mechanistic insights into the inhibition of biofilm formation and antibacterial action of endophytic Streptomyces strain KJ7TB2 isolated from the Indian Sundarbans Mangrove estuary
To explore the mechanism involved in the inhibition of biofilm formation and antibacterial action of endophytic Streptomyces sp. isolated from the Indian Sundarbans Mangrove Forest. In this study, Streptomyces sp. KJ7TB2 was isolated from the Indian Sundarbans. An ethyl acetate extract was subjected for GC-MS profiling. The mechanisms of antibacterial and antibiofilm action were also explored. In-silico molecular docking and dynamics simulation analyses were performed. The GC-MS analysis of the extract revealed 14 distinct bioactive secondary metabolites. The extract exhibited potent MIC values of 250 μg/mL and 125 μg/mL against Escherichia coli MTCC 1195 and Pseudomonas aeruginosa ATCC 27853. Antibiofilm investigation further revealed inhibition of biofilm formation in both pathogens especially in E. coli MTCC 1195, likely by disrupting initial surface adhesion and exopolysaccharide synthesis. Also, the extract inhibited swarming motility, suggesting interference with flagella-driven motility and quorum sensing. The brine shrimp lethality assay confirmed a favorable safety profile, recording limited mortality (36.84% at 2×MIC over 24 h). In-silico molecular docking and dynamics simulation analyses exhibited robust affinity for two key biofilm-associated proteins, exhibiting significant binding energy (ΔG). The study highlights Streptomyces sp. KJ7TB2 as a potential source for the discovery of safe, potent therapeutics.
- 12 May 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 18, 1-19
Genetic Framework of Migraine: An Insight into the Genetic Alterations and Novel Pharmacotherapeutic Approaches of Migraine Disorder
Introduction: Migraine and cluster headaches are common primary headache disorders that substantially impair quality of life and increase healthcare burden. Treatment efficacy is often limited by variability in patient response, partly due to genetic factors. This review examines current acute and preventive therapies for migraine, with a focus on the influence of genetic variations. Methods: A literature review was performed on migraine pathophysiology, highlighting the trigeminovascular system and genetic contributions, particularly in familial hemiplegic migraine. Pharmacological interventions assessed included triptans, NSAIDs, anticonvulsants, antidepressants, calcium channel blockers, and emerging agents such as CGRP-targeted antibodies, gepants, and relaxants. The impact of genetic variations on drug efficacy, metabolism, and safety was also evaluated. Results: Genetic mutations affect both migraine susceptibility and therapeutic response. Triptans and NSAIDs remain first-line acute treatments, whereas anticonvulsants, antidepressants, and calcium channel blockers are commonly used for prophylaxis. Emerging CGRP-targeted therapies and gepants provide effective alternatives for patients with inadequate responses to conventional therapies. Genetic polymorphisms may modify pharmacokinetics and pharmacodynamics, supporting personalized treatment strategies. Discussion: The interconnection between genetics and pharmacological response underscores the importance of individualized treatment. While traditional therapies remain effective for many years, emerging agents provide options for refractory cases. Understanding genetic contributions can guide therapy selection, optimize efficacy, and minimize adverse effects. Conclusion: Migraine management relies on traditional pharmacological agents alongside emerging therapies targeting CGRP pathways. Genetic variations significantly influence disease susceptibility, treatment response, and safety. Integrating genetic insights into clinical practice can optimize therapeutic outcomes and advance personalized management strategies for patients with primary headache disorders.
- 12 May 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Research Reviews
- Vol. 18, 1-19
Genetic Framework of Migraine: An Insight into the Genetic Alterations and Novel Pharmacotherapeutic Approaches of Migraine Disorder
Introduction: Migraine and cluster headaches are common primary headache disorders that substantially impair quality of life and increase healthcare burden. Treatment efficacy is often limited by variability in patient response, partly due to genetic factors. This review examines current acute and preventive therapies for migraine, with a focus on the influence of genetic variations. Methods: A literature review was performed on migraine pathophysiology, highlighting the trigeminovascular system and genetic contributions, particularly in familial hemiplegic migraine. Pharmacological interventions assessed included triptans, NSAIDs, anticonvulsants, antidepressants, calcium channel blockers, and emerging agents such as CGRP-targeted antibodies, gepants, and relaxants. The impact of genetic variations on drug efficacy, metabolism, and safety was also evaluated. Results: Genetic mutations affect both migraine susceptibility and therapeutic response. Triptans and NSAIDs remain first-line acute treatments, whereas anticonvulsants, antidepressants, and calcium channel blockers are commonly used for prophylaxis. Emerging CGRP-targeted therapies and gepants provide effective alternatives for patients with inadequate responses to conventional therapies. Genetic polymorphisms may modify pharmacokinetics and pharmacodynamics, supporting personalized treatment strategies. Discussion: The interconnection between genetics and pharmacological response underscores the importance of individualized treatment. While traditional therapies remain effective for many years, emerging agents provide options for refractory cases. Understanding genetic contributions can guide therapy selection, optimize efficacy, and minimize adverse effects. Conclusion: Migraine management relies on traditional pharmacological agents alongside emerging therapies targeting CGRP pathways. Genetic variations significantly influence disease susceptibility, treatment response, and safety. Integrating genetic insights into clinical practice can optimize therapeutic outcomes and advance personalized management strategies for patients with primary headache disorders.
- 10 October 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (12) , e01947
Inhibition of Biofilm Formation and Cell Wall Targeting Activity of Endophytic Nocardiopsis Strain KDCGRAW Isolated From the Indian Sundarbans
The discovery of new antimicrobials is one of the most crucial approaches to tackling the antimicrobial resistance crisis. Strain KDCGRAW was isolated from the root of Rhizophora apiculata (Garjan tree) from the Bonnie camp subdivision of Sundarbans, West Bengal, India. 16S rRNA gene sequencing analysis revealed that the strain belongs to the genus Nocardiopsis . The strain was subjected to fermentation, and the crude extract was analyzed using GC–MS. The extract inhibited Escherichia coli MTCC 1195 biofilm formation and showed a percentage biofilm remaining of 77.69% for 1/2 MIC, 69.18% for MIC, and 51.56% for 2 MIC, respectively. However, MIC and 2 MIC doses of the extract showed a significant biofilm formation inhibition and the percentage biofilm remaining determined was 51.89% and 43.97%, respectively, as compared to the 1/2 MIC 74.93% against Staphylococcus aureus MTCC 2940. The in silico docking and molecular dynamics study revealed that compound 1 and compound 9 exhibited the best docking energies with the two selected biofilm‐associated proteins, achieving binding energies of −6.84 and −7.7 kcal/mol on 5XP0 and 7C7R, respectively. In vivo toxicity analysis using brine shrimp revealed that the extract was nontoxic at all the concentration ranges, namely, 1/2 MIC, MIC, and 2 MIC.
- 10 October 2025
- Published by Wiley in Chemistry & Biodiversity
- Vol. 22 (12) , e01947
Inhibition of Biofilm Formation and Cell Wall Targeting Activity of Endophytic Nocardiopsis Strain KDCGRAW Isolated From the Indian Sundarbans
The discovery of new antimicrobials is one of the most crucial approaches to tackling the antimicrobial resistance crisis. Strain KDCGRAW was isolated from the root of Rhizophora apiculata (Garjan tree) from the Bonnie camp subdivision of Sundarbans, West Bengal, India. 16S rRNA gene sequencing analysis revealed that the strain belongs to the genus Nocardiopsis . The strain was subjected to fermentation, and the crude extract was analyzed using GC–MS. The extract inhibited Escherichia coli MTCC 1195 biofilm formation and showed a percentage biofilm remaining of 77.69% for 1/2 MIC, 69.18% for MIC, and 51.56% for 2 MIC, respectively. However, MIC and 2 MIC doses of the extract showed a significant biofilm formation inhibition and the percentage biofilm remaining determined was 51.89% and 43.97%, respectively, as compared to the 1/2 MIC 74.93% against Staphylococcus aureus MTCC 2940. The in silico docking and molecular dynamics study revealed that compound 1 and compound 9 exhibited the best docking energies with the two selected biofilm‐associated proteins, achieving binding energies of −6.84 and −7.7 kcal/mol on 5XP0 and 7C7R, respectively. In vivo toxicity analysis using brine shrimp revealed that the extract was nontoxic at all the concentration ranges, namely, 1/2 MIC, MIC, and 2 MIC.
- 1 September 2025
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 25 (6) , 40-55
Exploration of Phytochemicals as Anti-biofilm Agents against Pathogenic Bacteria: Their Potential and Challenges
Multicellular surface-attached populations of bacteria embedded in the extracellular matrix are known as biofilms. Bacteria generally preferred to grow as biofilms. Quorum sensing (QS), detection of density of cell population through gene regulation, has been found to play an important role in the production of biofilms. Biofilm formation can increase the severity of infections that can lead to morbidity or mortality. Bacteria living within biofilms have a higher pattern of adaptive resistance to antibiotics. Antibiotic resistance is a barrier in the treatment of biofilmsinduced acute to chronic infections such as post-surgery infections, surgery-associated wound infections, endocarditis, joint infections, burn-related wound infections occurred, ventilator-associated pneumonia, etc. So it is urgent to discover or find out potent new drugs in fight against infectious diseases such as biofilms-associated infections. Medicinal plants or herbs are a rich source for fighting with biofilms-mediated infections. Phytochemicals have exhibited significant effects in the prevention of biofilms formation against different bacteria that are causing infections. Purified compounds such as berberine, tetrandrine, embelin, xanthorrhizol, bakuchiol, etc., exhibited promising biofilm inhibition actions against different pathogenic bacteria. Plant extracts that contain several phytochemicals are evaluated for its biofilm’s inhibition property, and have shown significant potential in biofilm formation. Antibiofilm agents act by distinct mechanisms such as inhibiting the adherence of biofilms in a surface, preventing the biofilm formations, disrupting the matured biofilms, etc. This study is intended to reiterate about possibilities of plant extracts and purified compounds in the treatment of the prevention of bacterial biofilms-related infections.
- 1 September 2025
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 25 (6) , 40-55
Exploration of Phytochemicals as Anti-biofilm Agents against Pathogenic Bacteria: Their Potential and Challenges
Multicellular surface-attached populations of bacteria embedded in the extracellular matrix are known as biofilms. Bacteria generally preferred to grow as biofilms. Quorum sensing (QS), detection of density of cell population through gene regulation, has been found to play an important role in the production of biofilms. Biofilm formation can increase the severity of infections that can lead to morbidity or mortality. Bacteria living within biofilms have a higher pattern of adaptive resistance to antibiotics. Antibiotic resistance is a barrier in the treatment of biofilmsinduced acute to chronic infections such as post-surgery infections, surgery-associated wound infections, endocarditis, joint infections, burn-related wound infections occurred, ventilator-associated pneumonia, etc. So it is urgent to discover or find out potent new drugs in fight against infectious diseases such as biofilms-associated infections. Medicinal plants or herbs are a rich source for fighting with biofilms-mediated infections. Phytochemicals have exhibited significant effects in the prevention of biofilms formation against different bacteria that are causing infections. Purified compounds such as berberine, tetrandrine, embelin, xanthorrhizol, bakuchiol, etc., exhibited promising biofilm inhibition actions against different pathogenic bacteria. Plant extracts that contain several phytochemicals are evaluated for its biofilm’s inhibition property, and have shown significant potential in biofilm formation. Antibiofilm agents act by distinct mechanisms such as inhibiting the adherence of biofilms in a surface, preventing the biofilm formations, disrupting the matured biofilms, etc. This study is intended to reiterate about possibilities of plant extracts and purified compounds in the treatment of the prevention of bacterial biofilms-related infections.
- Open Access
- 7 December 2020
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 32 (12) , 3093-3096
Isolation and Characterization of Bioactive Anti-inflammatory Flavonoids from Arisaema tortuosum Tubers
Present study was focused on the isolation and characterization of the anti-inflammatory compound(s) from the methanolic extracts of Arisaema tortuosum tuber by column chromatography, TLC, FT-IR, 1H, 13C NMR and HR-MS. Among all the fractions obtained A. tortuosum fraction 3 (PC-1) and fraction 5 (PC-2) showed significant in vivo anti-inflammatory activity. This study endorsed that the isolated bioactive compound PC-2 showed better anti-inflammatory activity at a dose of 25 mg/Kg BW. The results indicate that PC-2 and PC-1 methanolic extract of A. tortuosum tuber may be competing for the tent in the therapy of inflammatory ailments.
- 7 December 2020
- Published by Asian Publication Corporation in Asian Journal of Chemistry
- Vol. 32 (12) , 3093-3096
Open AccessIsolation and Characterization of Bioactive Anti-inflammatory Flavonoids from Arisaema tortuosum Tubers
Present study was focused on the isolation and characterization of the anti-inflammatory compound(s) from the methanolic extracts of Arisaema tortuosum tuber by column chromatography, TLC, FT-IR, 1H, 13C NMR and HR-MS. Among all the fractions obtained A. tortuosum fraction 3 (PC-1) and fraction 5 (PC-2) showed significant in vivo anti-inflammatory activity. This study endorsed that the isolated bioactive compound PC-2 showed better anti-inflammatory activity at a dose of 25 mg/Kg BW. The results indicate that PC-2 and PC-1 methanolic extract of A. tortuosum tuber may be competing for the tent in the therapy of inflammatory ailments.